In the BEAT-ROP trial, ophthalmic follow-up at 2.5 years described a lower prevalence of very high myopia (defined as –8D or worse) following anti-VEGF treatment compared with laser therapy.14 The gene discussed is VEGFA; the disease is retinopathy of prematurity.